Rock Inhibitor Netarsudil for the Management of Glaucoma: EXPERT INSIGHTS AND CASE STUDY REVIEWS

August 5, 2020

Aerie Pharmaceuticals convened a group of expert thought leaders in the diagnosis and management of glaucoma to share their insights and experience with Rhopressa® and Rocklatan®, using case studies of patients in their practices as examples, including such topics as the rationale for treatment, efficacy and safety outcomes, ideal candidates for therapy, and managing patient expectations.

Sponsored by: Aerie Pharmaceuticals, Inc.